...
首页> 外文期刊>Clinical Pharmacology: Advances and Applications >Intrapleural therapy in management of complicated parapneumonic effusions and empyema
【24h】

Intrapleural therapy in management of complicated parapneumonic effusions and empyema

机译:胸膜内治疗复杂性肺炎旁积液和脓胸

获取原文

摘要

Abstract: Empyema thoracis causes high mortality, and its incidence is increasing in both children and adults. Parapneumonic effusions (PPEs) develop in about one-half of patients hospitalized with pneumonia, and their presence increases mortality by about four-fold. PPEs can be divided into simple PPEs, complicated PPEs, and frank empyema. Two guideline statements on the management of PPEs in adults have been published by the British Thoracic Society (BTS) and the American College of Chest Physicians; a third guideline statement published by the BTS focused on management of PPEs in children. The two adult guideline statements recommend drainage of the pleural space in complicated PPEs and frank empyema. They also recommend the use of intrapleural fibrinolysis in those who do not show improvement. The pediatric guideline statement recommends adding intrapleural fibrinolysis to those treated by tube thoracostomy if they have loculated pleural space or thick pus. Published guideline statements on the management of complicated PPEs and empyema in adults and children recommend the use of intrapleural fibrinolysis in those who do not show improvement after pleural space drainage. However, published clinical trial reports on the use of intrapleural fibrinolysis for the treatment of pleural space sepsis suffer from major design and methodologic limitations. Nevertheless, published reports have shown that the use of intrapleural fibrinolysis does not reduce mortality in adults with parapneumonic effusions and empyema. However, intrapleural fibrinolysis enhances drainage of infected pleural fluid and may be used in patients with large collections of infected pleural fluid causing breathlessness or respiratory failure, but a proportion of these patients will ultimately need surgery for definite cure. Intrapleural streptokinase and urokinase seem to be equally efficacious in enhancing infected pleural fluid drainage in adults. In most of the published studies in adults, the use of intrapleural fibrinolysis was not associated with serious side effects. There is emerging evidence that the combination of intrapleural tissue plasminogen activator (tPA) and deoxyribonuclease (DNase) is significantly superior to tPA or DNase alone or placebo in improving pleural fluid drainage in patients with pleural space infection. In children, intrapleural fibrinolysis has not been shown to reduce mortality, but has been shown to enhance drainage of the pleural space and was safe. In addition, two prospective, randomized trials have shown that intrapleural fibrinolysis is as effective as video-assisted thoracoscopic surgery for the treatment of childhood empyema and is a more cost-effective treatment and therefore should be the primary treatment of choice.
机译:摘要:脓胸可导致高死亡率,其发病率在儿童和成人中均在增加。大约一半的肺炎住院患者会出现肺炎旁积液(PPEs),它们的存在使死亡率增加约四倍。 PPE可以分为简单PPE,复杂PPE和坦白的脓胸。英国胸科学会(BTS)和美国胸科医师学会已经发表了两篇有关成人PPE管理的指南声明;防弹少年团发布的第三份准则声明主要针对儿童中个人防护装备的管理。两条成人指南声明建议引流复杂PPE和坦白脓胸中的胸膜腔。他们还建议在没有改善的患者中使用胸膜内纤溶治疗。儿科指南声明建议,如果导管胸腔穿刺术定位于胸膜间隙或脓液较厚,则应增加胸膜内纤溶治疗。已发表的有关成人和儿童复杂PPE和脓胸管理的指南声明建议对胸膜腔引流后未见改善的患者使用胸膜内纤溶。然而,关于使用胸膜内纤溶治疗胸膜腔脓毒症的已发表临床试验报告受到主要设计和方法学限制。然而,已发表的报告表明,胸膜内纤溶治疗并不能降低成人肺炎旁肺积液和脓胸的死亡率。但是,胸膜内纤维蛋白溶解会增加被感染胸膜液的引流,可用于有大量被感染胸膜液导致呼吸困难或呼吸衰竭的患者,但是这些患者中有一部分最终将需要手术以明确治愈。胸膜内链激酶和尿激酶似乎在增强成人感染胸腔积液引流方面同样有效。在大多数已发表的成人研究中,胸膜内纤维蛋白溶解的使用与严重的副作用无关。越来越多的证据表明,胸膜内组织纤溶酶原激活剂(tPA)和脱氧核糖核酸酶(DNase)的组合在改善胸膜腔感染患者的胸膜引流方面明显优于单独的tPA或DNase或安慰剂。在儿童中,胸膜内纤维蛋白溶解尚无降低死亡率的证据,但已证明可增加胸膜腔的引流,因此是安全的。此外,两项前瞻性随机试验表明,胸膜内纤维蛋白溶解治疗儿童胸腔积液与电视胸腔镜手术一样有效,是一种更具成本效益的治疗方法,因此应作为首选治疗方法。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号